The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated substantial returns, the lapse of its exclusive rights opened the floodgates to off-brand https://listbell.com/story11568709/sildenafil-and-big-pharma-a-risky-opportunity